{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:31:01Z","timestamp":1768433461381,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11864-021-00871-y","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T13:02:47Z","timestamp":1625230967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-2713","authenticated-orcid":false,"given":"Lisa","family":"Sudmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"871_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y.","journal-title":"Curr Oncol Rep"},{"key":"871_CR2","doi-asserted-by":"publisher","unstructured":"Achrol AS, et al. Brain metastases. Nat Rev Dis Primers. 2019;5. https:\/\/doi.org\/10.1038\/s41572-018-0055-y.","DOI":"10.1038\/s41572-018-0055-y"},{"key":"871_CR3","doi-asserted-by":"publisher","unstructured":"Berghoff AS, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1:e000024\u20134. https:\/\/doi.org\/10.1136\/esmoopen-2015-000024.","DOI":"10.1136\/esmoopen-2015-000024"},{"key":"871_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cllc.2019.12.001","volume":"21","author":"CM Karacz","year":"2020","unstructured":"Karacz CM, Yan J, Zhu H, Gerber DE. Timing, sites, and correlates of lung cancer recurrence. Clin Lung Cancer. 2020;21:127\u2013135.e123. https:\/\/doi.org\/10.1016\/j.cllc.2019.12.001.","journal-title":"Clin Lung Cancer"},{"key":"871_CR5","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.3747\/co.20.1481","volume":"20","author":"A Ali","year":"2013","unstructured":"Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol (Toronto, Ont). 2013;20:e300\u20136. https:\/\/doi.org\/10.3747\/co.20.1481.","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"871_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/bf02782192","volume":"17","author":"W Hall","year":"2000","unstructured":"Hall W, Djalilian H, Nussbaum E, Cho K. Long-term survival with metastatic cancer to the brain. Med Oncol. 2000;17:279\u201386. https:\/\/doi.org\/10.1007\/bf02782192.","journal-title":"Med Oncol"},{"key":"871_CR7","first-page":"33","volume":"10","author":"AT Leibold","year":"2019","unstructured":"Leibold AT, Monaco GN, Dey M. The role of the immune system in brain metastasis. Curr Neurobiol. 2019;10:33\u201348.","journal-title":"Curr Neurobiol"},{"key":"871_CR8","doi-asserted-by":"crossref","unstructured":"McTyre ER, et al. Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy. 2016:now184, doi:10.1093\/neuonc\/now184","DOI":"10.1093\/neuonc\/now184"},{"key":"871_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/neuonc\/noz246","volume":"22","author":"RR Patel","year":"2020","unstructured":"Patel RR, et al. Exclusion of patients with brain metastases from cancer clinical trials. Neuro-Oncology. 2020;22:577\u20139. https:\/\/doi.org\/10.1093\/neuonc\/noz246.","journal-title":"Neuro-Oncology"},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ctrv.2018.05.015","volume":"68","author":"E El Rassy","year":"2018","unstructured":"El Rassy E, et al. Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment. Cancer Treat Rev. 2018;68:69\u201379. https:\/\/doi.org\/10.1016\/j.ctrv.2018.05.015.","journal-title":"Cancer Treat Rev"},{"key":"871_CR11","doi-asserted-by":"publisher","unstructured":"\u2022 Sperduto PW, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38:3773\u201384. https:\/\/doi.org\/10.1200\/jco.20.01255 This article defines the updated GPA for patients with brain metastases and demonstrates how survival has improved but varies depending on GPA.","DOI":"10.1200\/jco.20.01255"},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar SN, et al. Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018;19:e373\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.007.","journal-title":"Clin Lung Cancer"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamaoncol.2018.4610","volume":"5","author":"TM Churilla","year":"2019","unstructured":"Churilla TM, et al. Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection. JAMA Oncology. 2019;5:243. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4610.","journal-title":"JAMA Oncology"},{"key":"871_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u201371. https:\/\/doi.org\/10.1038\/nature13954.","journal-title":"Nature"},{"key":"871_CR15","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"key":"871_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"871_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/nejmoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333. https:\/\/doi.org\/10.1056\/nejmoa1606774.","journal-title":"N Engl J Med"},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"key":"871_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537\u201346. https:\/\/doi.org\/10.1200\/JCO.18.00149.","journal-title":"J Clin Oncol"},{"key":"871_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/jco.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"\u2022 Gadgeel S, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38:1505\u201317. https:\/\/doi.org\/10.1200\/jco.19.03136 This updated analysis of KEYNOTE-189 showed that the survival benefit of pembrolizumab was seen regardless of whether or not patients had brain metastases.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"871_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(16)32517-x","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255\u201365. https:\/\/doi.org\/10.1016\/s0140-6736(16)32517-x.","journal-title":"Lancet"},{"key":"871_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","volume":"128","author":"SM Gadgeel","year":"2019","unstructured":"Gadgeel SM, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study. Lung cancer (Amsterdam, Netherlands). 2019;128:105\u201312. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.017.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"key":"871_CR23","doi-asserted-by":"publisher","first-page":"v604","DOI":"10.1093\/annonc\/mdz260.004","volume":"30","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, et al. 1482O - Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1\u2013positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, -010, -024, and -042. Ann Oncol. 2019;30:v604\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdz260.004.","journal-title":"Ann Oncol"},{"key":"871_CR24","doi-asserted-by":"publisher","first-page":"v606","DOI":"10.1093\/annonc\/mdz260.005","volume":"30","author":"SF Powell","year":"2019","unstructured":"Powell SF, et al. 1483PD - Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: pooled analysis of KEYNOTE-021, 189, and 407. Ann Oncol. 2019;30:v606\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdz260.005.","journal-title":"Ann Oncol"},{"key":"871_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3747\/co.25.4287","volume":"25","author":"RA Juergens","year":"2018","unstructured":"Juergens RA, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol (Toronto, Ont). 2018;25:384\u201392. https:\/\/doi.org\/10.3747\/co.25.4287.","journal-title":"Curr Oncol (Toronto, Ont)"},{"key":"871_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.21037\/tlcr.2018.04.03","volume":"7","author":"MC Areses Manrique","year":"2018","unstructured":"Areses Manrique MC, et al. Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res. 2018;7:404\u201315. https:\/\/doi.org\/10.21037\/tlcr.2018.04.03.","journal-title":"Transl Lung Cancer Res"},{"key":"871_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","volume":"129","author":"L Crin\u00f2","year":"2019","unstructured":"Crin\u00f2 L, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2019;129:35\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.025.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"871_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/s1470-2045(20)30111-x","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"\u2022\u2022 Goldberg SB, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. The Lancet Oncology. 2020;21:655\u201363. https:\/\/doi.org\/10.1016\/s1470-2045(20)30111-x This phase II study specifically evaluated whether ICB has efficacy in untreated brain metastases.","journal-title":"The Lancet Oncology"},{"key":"871_CR29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019;14:1244\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"871_CR30","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3171\/jns.2006.104.6.907","volume":"104","author":"MA Vogelbaum","year":"2006","unstructured":"Vogelbaum MA, et al. Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin. J Neurosurg. 2006;104:907\u201312. https:\/\/doi.org\/10.3171\/jns.2006.104.6.907.","journal-title":"J Neurosurg"},{"key":"871_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","volume":"100","author":"L Chen","year":"2018","unstructured":"Chen L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100:916\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","volume":"101","author":"E Schapira","year":"2018","unstructured":"Schapira E, et al. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys. 2018;101:624\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.175.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","volume":"13","author":"HG Hubbeling","year":"2018","unstructured":"Hubbeling HG, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13:550\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.01.012.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"871_CR34","doi-asserted-by":"publisher","unstructured":"Shepard MJ, et al. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. J Neurosurg. 2019:1\u20138. https:\/\/doi.org\/10.3171\/2019.4.jns19822.","DOI":"10.3171\/2019.4.jns19822"},{"key":"871_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10555-020-09949-9","volume":"40","author":"PY Borius","year":"2021","unstructured":"Borius PY, et al. Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and\/or immunotherapy) in brain metastases: a systematic review. Cancer Metastasis Rev. 2021;40:341\u201354. https:\/\/doi.org\/10.1007\/s10555-020-09949-9.","journal-title":"Cancer Metastasis Rev"},{"key":"871_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","volume":"21","author":"R Kotecha","year":"2019","unstructured":"Kotecha R, et al. The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology. 2019;21:1060\u20138. https:\/\/doi.org\/10.1093\/neuonc\/noz046.","journal-title":"Neuro-Oncology"},{"key":"871_CR37","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1002\/cncr.33196","volume":"126","author":"JM Qian","year":"2020","unstructured":"Qian JM, et al. Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. Cancer. 2020;126:5274\u201382. https:\/\/doi.org\/10.1002\/cncr.33196.","journal-title":"Cancer"},{"key":"871_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Lehrer, E. J. et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130, 104-112, doi:10.1016\/j.radonc.2018.08.025 (2019). This meta-analysis showed an overall survival benefit to concurrent ICB with SRS over non-concurrent ICB and SRS.","DOI":"10.1016\/j.radonc.2018.08.025"},{"key":"871_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401\u20139. https:\/\/doi.org\/10.1001\/jama.2016.9839.","journal-title":"JAMA"},{"key":"871_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/s1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology. 2017;18:1049\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(17)30441-2.","journal-title":"The Lancet Oncology"},{"key":"871_CR41","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","volume":"295","author":"H Aoyama","year":"2006","unstructured":"Aoyama H, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483\u201391. https:\/\/doi.org\/10.1001\/jama.295.21.2483.","journal-title":"JAMA"},{"key":"871_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","volume":"99","author":"M Yamamoto","year":"2017","unstructured":"Yamamoto M, et al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 study update): irradiation-related complications and long-term maintenance of Mini-Mental State Examination scores. Int J Radiat Oncol Biol Phys. 2017;99:31\u201340. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.04.037.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ijrobp.2019.03.052","volume":"104","author":"RT Hughes","year":"2019","unstructured":"\u2022 Hughes RT, et al. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys. 2019;104:1091\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.052 This retrospective study showed no difference in overall survival between patients with 2\u20134 vs 5\u201315 brain metastases treated with SRS.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR44","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/not114","volume":"15","author":"PD Brown","year":"2013","unstructured":"Brown PD, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 2013;15:1429\u201337. https:\/\/doi.org\/10.1093\/neuonc\/not114.","journal-title":"Neuro-Oncology"},{"key":"871_CR45","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/jco.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38:1019\u201329. https:\/\/doi.org\/10.1200\/jco.19.02767.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"871_CR46","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2169\/internalmedicine.4232-19","volume":"59","author":"K Nakashima","year":"2020","unstructured":"Nakashima K, et al. Whole-brain radiation and pembrolizumab treatment for a non-small-cell lung cancer patient with meningeal carcinomatosis lacking driver oncogenes led to a long-term survival. Internal medicine (Tokyo, Japan). 2020;59:1433\u20135. https:\/\/doi.org\/10.2169\/internalmedicine.4232-19.","journal-title":"Internal medicine (Tokyo, Japan)"},{"key":"871_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijrobp.2017.05.028","volume":"99","author":"NL Williams","year":"2017","unstructured":"Williams NL, et al. Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys. 2017;99:22\u201330. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.05.028.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR48","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.21037\/tlcr.2019.05.15","volume":"8","author":"M Nishino","year":"2019","unstructured":"Nishino M, Soejima K, Mitsudomi T. Brain metastases in oncogene-driven non-small cell lung cancer. Translational Lung Cancer Research. 2019;8:S298\u2013307. https:\/\/doi.org\/10.21037\/tlcr.2019.05.15.","journal-title":"Translational Lung Cancer Research"},{"key":"871_CR49","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.21037\/tlcr.2019.12.24","volume":"8","author":"A Spagnuolo","year":"2019","unstructured":"Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res. 2019;8:1134\u201351. https:\/\/doi.org\/10.21037\/tlcr.2019.12.24.","journal-title":"Transl Lung Cancer Res"},{"key":"871_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ctrv.2018.10.011","volume":"71","author":"A Wrona","year":"2018","unstructured":"Wrona A, Dziadziuszko R, Jassem J. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. Cancer Treat Rev. 2018;71:59\u201367. https:\/\/doi.org\/10.1016\/j.ctrv.2018.10.011.","journal-title":"Cancer Treat Rev"},{"key":"871_CR51","doi-asserted-by":"publisher","unstructured":"Mazieres J, et al. Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). J Clin Oncol. 2018;36:9010\u20130. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.9010.","DOI":"10.1200\/JCO.2018.36.15_suppl.9010"},{"key":"871_CR52","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ijrobp.2020.07.2108","volume":"108","author":"J Li","year":"2020","unstructured":"Li J, et al. Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: a phase III randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020;108:S21\u20132. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.07.2108.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"871_CR53","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/s0140-6736(16)30825-x","volume":"388","author":"P Mulvenna","year":"2016","unstructured":"Mulvenna P, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(16)30825-x.","journal-title":"Lancet"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00871-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T16:45:39Z","timestamp":1630082739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00871-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00871-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"20 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lisa Sudmeier declares that she has no conflict of interest. Sibo Tian declares that he has no conflict of interest. Kristin A. Higgins has received research funding from RefleXion; has received compensation from AstraZeneca for participating on an advisory board; and has received honoraria from PrecisCa.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"77"}}